On Monday, H.C. Wainwright initiated coverage on Arcus Biosciences (NYSE:RCUS) with a Neutral rating and a price target of $20.00. The firm's stance is based on the anticipation that upcoming data releases for the company's drug candidates will not significantly stand out from those of competitors.
Arcus Biosciences, a late-stage immuno-oncology company, is developing a diverse portfolio of assets, including casdatifan (cas), domvanalimab (dom), quemliclustat (quemli), and etrumadenant (etruma).
The analyst noted that while there is optimism regarding casdatifan due to its validation as a target against clear cell renal cell carcinoma, the expected objective response rate (ORR) from the upcoming data release on October 24 may not exceed the 20-25% observed with competitor belzutifan in LITESPARK studies.
Arcus has indicated lower progressive disease rates in comparison to the belzutifan Phase 3 LITESPARK-005 study, but the analyst suggests that a significant ORR improvement would be required to generate excitement due to the small patient sample in the ARC-20 study.
The firm also expressed concerns about the differentiation of Arcus's TIGIT inhibitor, domvanalimab, from other treatments in the space, especially given the discontinuation of many similar programs. The lack of significant differentiation in earlier stage data from the ARC-7 study for 1st line non-small cell lung cancer (NSCLC) also adds to the firm's cautious outlook.
Despite these reservations, there is a higher degree of confidence in the Phase 3 STAR-221 study in 1st line gastric cancer, which has shown a progression-free survival benefit. Key opinion leaders consulted by the firm also expressed more enthusiasm for the STAR-121 study, though the overall survival endpoint has not been disclosed for the EDGE-Gastric study.
Looking ahead, full randomized data from the ARC-10 study in 1st line NSCLC, which evaluates domvanalimab in combination with zimberelimab versus zimberelimab alone versus chemotherapy, is expected in the fourth quarter of 2024. However, the firm remains cautious, doubting that this data will mark a significant departure from the earlier ARC-7 study results.
In other recent news, Arcus Biosciences reported a promising Q1 2024 performance, with GAAP revenue of $145 million and cash reserves of $1.1 billion, exceeding consensus estimates. This financial health was driven by an $11 million increase in collaboration revenues.
Furthermore, Arcus Biosciences announced a strategic partnership with AstraZeneca (NASDAQ:AZN), a collaboration expected to enhance the development of the novel bispecific antibody, Volrustomig, targeting PD-1 and CTLA4. Truist Securities maintained a Buy rating on Arcus Biosciences, expressing confidence in the company's strategic direction and the anticipated impact of its collaboration with AstraZeneca.
The company has also been active in its product pipeline, expanding enrollment for the 100mg arm of its study, introducing an additional cas plus cabo arm, and preparing to initiate a phase 3 trial in the first half of 2025.
Despite a pause on Roche's Phase 2/3 SKYSCRAPER-06 study, Cantor Fitzgerald maintained an Overweight rating on Arcus Biosciences, indicating a shift in focus from non-small cell lung cancer to upper gastrointestinal cancers.
On the other hand, BofA Securities revised its price target for Arcus Biosciences, reducing it to $23.00 from the previous $24.00, while maintaining a Neutral rating on the stock. Similarly, Barclays adjusted its outlook on shares of Arcus Biosciences, reducing the price target to $25.00 from the previous $35.00, but maintained an Overweight rating. These recent developments highlight the ongoing progress and potential of Arcus Biosciences in advancing its clinical programs.
InvestingPro Insights
To complement H.C. Wainwright's analysis of Arcus Biosciences (NYSE:RCUS), recent data from InvestingPro offers additional context for investors. Despite the neutral rating, RCUS has shown a strong return over the last three months, with a 29.13% price total return. This recent performance aligns with the company's upcoming data releases, which could be driving investor interest.
InvestingPro Tips highlight that Arcus Biosciences holds more cash than debt on its balance sheet, and its liquid assets exceed short-term obligations. These factors could provide the company with financial flexibility as it advances its drug candidates through clinical trials. However, it's worth noting that RCUS is quickly burning through cash and is not profitable over the last twelve months, which underscores the importance of successful clinical outcomes for its financial future.
Analysts anticipate sales growth in the current year, with revenue increasing by 104.13% in the last twelve months to $247 million. This growth trajectory could be crucial as the company works to differentiate its products in the competitive immuno-oncology space.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for RCUS, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.